These results are consistent with previous studies showing either no or modest induction of BAX following treatment with MDM2 inhibitors (RG7388 and Nutlin-3a) in a panel of ovarian or cutaneous melanoma cell lines, respectively [25,41]. Here, MDM2 is linked to cutaneous melanoma.